JP7289306B2 - 網膜障害を治療するための組成物及び方法 - Google Patents

網膜障害を治療するための組成物及び方法 Download PDF

Info

Publication number
JP7289306B2
JP7289306B2 JP2020538584A JP2020538584A JP7289306B2 JP 7289306 B2 JP7289306 B2 JP 7289306B2 JP 2020538584 A JP2020538584 A JP 2020538584A JP 2020538584 A JP2020538584 A JP 2020538584A JP 7289306 B2 JP7289306 B2 JP 7289306B2
Authority
JP
Japan
Prior art keywords
seq
sequence
vector
tcu
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020538584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510301A (ja
JP2021510301A5 (https=
JPWO2019138250A5 (https=
Inventor
アリ，ロビン
マツキ，タカアキ
スミス，アレキサンダー
ジョージアディス，アナスタシオス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Biomedica PLC
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Biomedica PLC, UCL Business Ltd filed Critical UCL Biomedica PLC
Publication of JP2021510301A publication Critical patent/JP2021510301A/ja
Publication of JP2021510301A5 publication Critical patent/JP2021510301A5/ja
Publication of JPWO2019138250A5 publication Critical patent/JPWO2019138250A5/ja
Application granted granted Critical
Publication of JP7289306B2 publication Critical patent/JP7289306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020538584A 2018-01-12 2019-01-14 網膜障害を治療するための組成物及び方法 Active JP7289306B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1800546.2 2018-01-12
GBGB1800546.2A GB201800546D0 (en) 2018-01-12 2018-01-12 Treatment
PCT/GB2019/050092 WO2019138250A1 (en) 2018-01-12 2019-01-14 Compositions and methods for treating retinal disorders

Publications (4)

Publication Number Publication Date
JP2021510301A JP2021510301A (ja) 2021-04-22
JP2021510301A5 JP2021510301A5 (https=) 2022-01-21
JPWO2019138250A5 JPWO2019138250A5 (https=) 2022-01-21
JP7289306B2 true JP7289306B2 (ja) 2023-06-09

Family

ID=61256183

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020538584A Active JP7289306B2 (ja) 2018-01-12 2019-01-14 網膜障害を治療するための組成物及び方法

Country Status (26)

Country Link
US (2) US11680276B2 (https=)
EP (1) EP3737423B1 (https=)
JP (1) JP7289306B2 (https=)
KR (1) KR102786552B1 (https=)
CN (1) CN111936172A (https=)
AU (1) AU2019206314B2 (https=)
BR (1) BR112020014191A2 (https=)
CA (1) CA3088079A1 (https=)
DK (1) DK3737423T3 (https=)
EA (1) EA202091655A1 (https=)
ES (1) ES2988499T3 (https=)
FI (1) FI3737423T3 (https=)
GB (1) GB201800546D0 (https=)
HR (1) HRP20241483T1 (https=)
HU (1) HUE068987T2 (https=)
IL (1) IL275985A (https=)
LT (1) LT3737423T (https=)
MX (1) MX2020007366A (https=)
PH (1) PH12020551071A1 (https=)
PL (1) PL3737423T3 (https=)
PT (1) PT3737423T (https=)
RS (1) RS66227B1 (https=)
SG (1) SG11202006618PA (https=)
SI (1) SI3737423T1 (https=)
SM (1) SMT202400410T1 (https=)
WO (1) WO2019138250A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230058556A (ko) 2013-03-15 2023-05-03 아스텔라스 인스티튜트 포 리제너러티브 메디슨 만능 줄기 세포로부터 제조된 광수용기 및 광수용기 전구체
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
GB2584664B (en) * 2019-06-10 2023-05-24 Newcells Biotech Ltd Improved retinal organoids and methods of making the same
CN113025616B (zh) * 2021-04-21 2023-05-02 中国热带农业科学院橡胶研究所 一种橡胶树泛素基因启动子proHbUBI2及其克隆与应用
CN118076629A (zh) * 2021-05-20 2024-05-24 阿特玛治疗公司 Kcnv2变体及其用途
WO2023039175A2 (en) * 2021-09-09 2023-03-16 Applied Genetic Technologies Corporation Predictors of achromatopsia treatment efficacy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073303A2 (en) 2006-12-07 2008-06-19 Switchgear Genomics Transcriptional regulatory elements of biological pathways, tools, and methods
WO2011034947A2 (en) 2009-09-15 2011-03-24 University Of Washington Reagents and methods for modulating cone photoreceptor activity
JP2017510296A (ja) 2014-03-17 2017-04-13 アドヴェラム バイオテクノロジーズ， インコーポレイテッド 錐体細胞における増強された遺伝子発現のための組成物および方法
WO2017144080A1 (en) 2016-02-23 2017-08-31 Eyeserv Gmbh Gene therapy for the treatment of a disease of retinal cone cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3591055A1 (en) * 2011-01-07 2020-01-08 Applied Genetic Technologies Corporation Promoters derived from the 5' nontranslated region (5'-ntr) of the human cyclic nucleotide gated beta 3 (cngb3) gene, expression cassettes and vectors comprising said promoters, for use treating achromatopsia and other diseases
MY187898A (en) * 2015-03-02 2021-10-27 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073303A2 (en) 2006-12-07 2008-06-19 Switchgear Genomics Transcriptional regulatory elements of biological pathways, tools, and methods
WO2011034947A2 (en) 2009-09-15 2011-03-24 University Of Washington Reagents and methods for modulating cone photoreceptor activity
JP2017510296A (ja) 2014-03-17 2017-04-13 アドヴェラム バイオテクノロジーズ， インコーポレイテッド 錐体細胞における増強された遺伝子発現のための組成物および方法
WO2017144080A1 (en) 2016-02-23 2017-08-31 Eyeserv Gmbh Gene therapy for the treatment of a disease of retinal cone cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Human Gene Therapy (2016) Vol.27, No.1, pp.72-82
PNAS (2002) Vol.99, No.2, pp.1008-1011

Also Published As

Publication number Publication date
US12467066B2 (en) 2025-11-11
EP3737423B1 (en) 2024-09-18
PH12020551071A1 (en) 2021-09-06
CN111936172A (zh) 2020-11-13
JP2021510301A (ja) 2021-04-22
KR20200141435A (ko) 2020-12-18
EP3737423A1 (en) 2020-11-18
MX2020007366A (es) 2020-09-03
DK3737423T3 (da) 2024-10-21
AU2019206314B2 (en) 2025-02-13
IL275985A (en) 2020-08-31
KR102786552B1 (ko) 2025-03-26
SG11202006618PA (en) 2020-08-28
FI3737423T3 (fi) 2024-11-02
CA3088079A1 (en) 2019-07-18
AU2019206314A1 (en) 2020-08-13
HRP20241483T1 (hr) 2025-01-03
GB201800546D0 (en) 2018-02-28
NZ766316A (en) 2024-05-31
PL3737423T3 (pl) 2025-01-27
SMT202400410T1 (it) 2025-01-14
EA202091655A1 (ru) 2020-11-20
HUE068987T2 (hu) 2025-02-28
US11680276B2 (en) 2023-06-20
US20200392536A1 (en) 2020-12-17
RS66227B1 (sr) 2024-12-31
WO2019138250A1 (en) 2019-07-18
US20240067989A1 (en) 2024-02-29
BR112020014191A2 (pt) 2022-02-22
LT3737423T (lt) 2024-11-25
ES2988499T3 (es) 2024-11-20
PT3737423T (pt) 2024-10-03
SI3737423T1 (sl) 2025-03-31

Similar Documents

Publication Publication Date Title
JP7289306B2 (ja) 網膜障害を治療するための組成物及び方法
CA2873628C (en) Treatment of amd using aav sflt-1
KR102776626B1 (ko) Aav 벡터
JP2018529336A (ja) 網膜色素変性症の治療
JP2018512125A (ja) 多重ベクターシステム及びその使用
JP2018510620A (ja) 最適化されたｒｐｅ６５プロモーター及びコード配列
JP7766393B2 (ja) 眼疾患のための遺伝子療法
JP2019523648A (ja) Ａｂｃ４ａを発現させるためのデュアル重複アデノ随伴ウイルスベクターシステム
WO2025247393A1 (zh) 用于治疗Prom1相关视网膜疾病的新型治疗药物
JP7287611B2 (ja) 改良型アデノ随伴ウイルスベクター
JP2022527116A (ja) Ｔｐｐ１を発現するａａｖの投与による眼のリソソーム蓄積症の治療
AU2020212026A1 (en) Highly efficient transduction and lateral spread in the retina by a novel AAV virus enhanced by rational design
WO2020000641A1 (zh) 编码人nadh脱氢酶亚单位蛋白的核酸及其应用
HK40030486A (en) Compositions and methods for treating retinal disorders
HK40030486B (en) Compositions and methods for treating retinal disorders
CA3131923A1 (en) Neuroprotective gene therapy targeting the akt pathway
EA046019B1 (ru) Композиции и способы лечения нарушений сетчатки
JP2021520231A (ja) シュタルガルト病の処置のための組成物及び方法
CN110167958A (zh) 载体介导的眼睛免疫耐受性
JP2024521713A (ja) Ｋｃｎｖ２変異体及びその使用
WO2025026182A1 (zh) 融合多肽、包含其编码基因的表达盒、基因递送载体、药物组合物及用途
HK40104787A (en) Treatment of amd using aav sflt-1
CA3231028A1 (en) Treatment of rpe65-associated eye diseases and disorders

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220113

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230530

R150 Certificate of patent or registration of utility model

Ref document number: 7289306

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150